Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Host cyclooxygenase-2 modulates carcinoma growth
Christopher S. Williams, … , Sudhansu K. Dey, Raymond N. DuBois
Christopher S. Williams, … , Sudhansu K. Dey, Raymond N. DuBois
Published June 1, 2000
Citation Information: J Clin Invest. 2000;105(11):1589-1594. https://doi.org/10.1172/JCI9621.
View: Text | PDF
Article

Host cyclooxygenase-2 modulates carcinoma growth

  • Text
  • PDF
Abstract

Cyclooxygenase-2 (COX-2; Ptgs2) acts as a tumor promoter in rodent models for colorectal cancer, but its precise role in carcinogenesis remains unclear. We evaluated the contribution of host-derived COX-1 and COX-2 in tumor growth using both genetic and pharmacological approaches. Lewis lung carcinoma (LLC) cells grow rapidly as solid tumors when implanted in C57BL/6 mice. We found that tumor growth was markedly attenuated in COX-2–/–, but not COX-1–/– or wild-type mice. Treatment of wild-type C57BL/6 mice bearing LLC tumors with a selective COX-2 inhibitor also reduced tumor growth. A decrease in vascular density was observed in tumors grown in COX-2–/– mice when compared with those in wild-type mice. Because COX-2 is expressed in stromal fibroblasts of human and rodent colorectal carcinomas, we evaluated COX-2–/– mouse fibroblasts and found a 94% reduction in their ability to produce the proangiogenic factor, VEGF. Additionally, treatment of wild-type mouse fibroblasts with a selective COX-2 inhibitor reduced VEGF production by 92%.

Authors

Christopher S. Williams, Masahiko Tsujii, Jeff Reese, Sudhansu K. Dey, Raymond N. DuBois

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Host-derived COX-2 is important for LLC tumor growth. (a) A total of 2 ×...
Host-derived COX-2 is important for LLC tumor growth. (a) A total of 2 × 106 LLC cells were implanted into COX-2+/+ (gray bars), COX-2+/– (white bars), or COX-2–/– (black bars) C57BL/6 mice; (b) a total of 2 × 106 LLC cells were implanted into COX-1+/+ (gray bars) or COX-1–/– (black bars) C57BL/6 mice. Tumor volumes were calculated from tumor measurements scored at the indicated day. Results are presented as the mean tumor volume ± SEM.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts